Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

27 avr. 2026 09h00 HE | Source: Portnoy Law

Portnoy Law Firm Announces Class Action on Behalf of ImmunityBio, Inc. Investors

LOS ANGELES, April 27, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises ImmunityBio, Inc., (“Super Micro” or the "Company") (NASDAQ: IBRX) investors of a class action on behalf of investors...
25 avr. 2026 09h11 HE | Source: The Rosen Law Firm PA

ROSEN, THE FIRST FILING FIRM, Encourages ImmunityBio, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - IBRX

NEW YORK, April 25, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ImmunityBio, Inc. (NASDAQ: IBRX) between January 19, 2026...
24 avr. 2026 22h12 HE | Source: Robbins Geller Rudman & Dowd LLP

IBRX INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that ImmunityBio, Inc. Investors with Substantial Losses Have Opportunity to Lead Securities Class Action Lawsuit

The case alleges ImmunityBio materially overstated Anktiva’s capabilities.
24 avr. 2026 15h30 HE | Source: Hagens Berman Sobol Shapiro LLP

IBRX Lawsuit Alleges Misleading Cancer Claims - ImmunityBio Investors Face Losses Following $2B Market Cap Loss – Hagens Berman

Investors who lost money in IBRX after its stock plunged due to allegedly misleading financial statements are urged to contact Hagens Berman.
24 avr. 2026 10h20 HE | Source: Schall Law

IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit with the Schall Law Firm

IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit with the Schall Law Firm
23 avr. 2026 11h05 HE | Source: SkyMedia, LLC

ImmunityBio Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against ImmunityBio, Inc. - IBRX

NEW ORLEANS, April 23, 2026 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until May 26, 2026 to file lead plaintiff applications in a...
23 avr. 2026 08h01 HE | Source: Bernstein Liebhard LLP

SHAREHOLDER ALERT Bernstein Liebhard LLP Securities Class Action Lawsuit Filed Against ImmunityBio, Inc. (IBRX)

ImmunityBio Shareholders Between January 19, 2026 and March 24, 2026 - Contact Bernstein Liebhard For More Information Regarding Shareholder Lawsuit
22 avr. 2026 21h00 HE | Source: Hagens Berman Sobol Shapiro LLP

IBRX SHAREHOLDER UPDATE: ImmunityBio (IBRX) Sued After FDA Flags Misleading Cancer Claims, Shares Plunge 21%, $2B Market Cap Lost -- Hagens Berman

Investors who lost money in IBRX after its stock plunged due to allegedly misleading financial statements are urged to contact Hagens Berman.
22 avr. 2026 16h56 HE | Source: The Rosen Law Firm PA

ROSEN, A LONGSTANDING LAW FIRM, Encourages ImmunityBio, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - IBRX

NEW YORK, April 22, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ImmunityBio, Inc. (NASDAQ: IBRX) between January 19, 2026...
21 avr. 2026 23h06 HE | Source: Kahn Swick & Foti, LLC

ImmunityBio, Inc. Securities Fraud Class Action Result of FDA Warning and 21% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC

ImmunityBio (IBRX) Investors Have Opportunity to Lead ImmunityBio, Inc Securities Fraud Lawsuit

Page suivante